These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138 [TBL] [Abstract][Full Text] [Related]
3. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493 [TBL] [Abstract][Full Text] [Related]
4. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. He Y; Su Z; Xue L; Xu H; Zhang C J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977 [TBL] [Abstract][Full Text] [Related]
5. Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method. Naseri N; Zakeri-Milani P; Hamishehkar H; Pilehvar-Soltanahmadi Y; Valizadeh H Drug Res (Stuttg); 2017 Jun; 67(6):343-348. PubMed ID: 28288490 [TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Xu H; He C; Liu Y; Jiang J; Ma T Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1902-1907. PubMed ID: 29081246 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticulation improves bioavailability of Erlotinib. Yang KM; Shin IC; Park JW; Kim KS; Kim DK; Park K; Kim K Drug Dev Ind Pharm; 2017 Sep; 43(9):1557-1565. PubMed ID: 28554216 [TBL] [Abstract][Full Text] [Related]
8. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer. Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759 [TBL] [Abstract][Full Text] [Related]
9. Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy. Fatani WK; Aleanizy FS; Alqahtani FY; Alanazi MM; Aldossari AA; Shakeel F; Haq N; Abdelhady H; Alkahtani HM; Alsarra IA Molecules; 2023 May; 28(9):. PubMed ID: 37175381 [TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Memon AA; Jakobsen S; Dagnaes-Hansen F; Sorensen BS; Keiding S; Nexo E Cancer Res; 2009 Feb; 69(3):873-8. PubMed ID: 19155297 [TBL] [Abstract][Full Text] [Related]
11. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Dora CP; Kushwah V; Katiyar SS; Kumar P; Pillay V; Suresh S; Jain S Int J Pharm; 2017 Dec; 534(1-2):1-13. PubMed ID: 28970115 [TBL] [Abstract][Full Text] [Related]
12. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416 [TBL] [Abstract][Full Text] [Related]
13. Metastasized lung cancer suppression by Morinda citrifolia (Noni) leaf compared to Erlotinib via anti-inflammatory, endogenous antioxidant responses and apoptotic gene activation. Lim SL; Mustapha NM; Goh YM; Bakar NA; Mohamed S Mol Cell Biochem; 2016 May; 416(1-2):85-97. PubMed ID: 27106908 [TBL] [Abstract][Full Text] [Related]
14. Quercitrin loaded cyclodextrin based nanosponge as a promising approach for management of lung cancer and COVID-19. Abou Taleb S; Moatasim Y; GabAllah M; Asfour MH J Drug Deliv Sci Technol; 2022 Nov; 77():103921. PubMed ID: 36338534 [TBL] [Abstract][Full Text] [Related]
15. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814 [TBL] [Abstract][Full Text] [Related]
16. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice. Li JY; Ren YP; Yuan Y; Ji SM; Zhou SP; Wang LJ; Mou ZZ; Li L; Lu W; Zhou TY Acta Pharmacol Sin; 2016 Jul; 37(7):930-40. PubMed ID: 27180983 [TBL] [Abstract][Full Text] [Related]